MedImmune not compelled to add RespiGam trials

MedImmune not compelled to add RespiGam trials

MedImmune Inc. (MEDI) has decided not to run any new trials of RespiGam, its polyclonal antibody to treat respiratory syncytial virus, despite the unanimous decision by the FDA Blood Products Advisory Committee last December to recommend against

Read the full 446 word article

How to gain access

Continue reading with a
two-week free trial.